AI English summary of an SEC filing — figures as filed
Abbott Laboratories ABTThe company said it completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion, paying $105 per share in cash. It said the deal was funded mainly through the issuance of $20 billion of long-term debt in March 2026, with the remainder funded by cash on hand.
Key points
AI summaryThe company said it completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion, paying $105 per share in cash. It said the deal was funded mainly through the issuance of $20 billion of long-term debt in March 2026, with the remainder funded by cash on hand.
The company said total net sales rose 3.8% in Q1 2026 excluding the impact of foreign exchange, mainly reflecting higher product sales in the Medical Devices and Established Pharmaceutical Products segments. It said Nutritional Products sales declined due to lower sales volumes.
Abbott said SG&A expenses rose $679 million to $3.7 billion, or 22.2%, in Q1 2026, citing the acquisition and integration of Exact Sciences and stock-based compensation expense from the cash-out of equity awards tied to the deal as the main factors. R&D expenses rose $51 million to $767 million.
The company said cash and cash equivalents fell from $8.5 billion on December 31, 2025 to $6.8 billion on March 31, 2026. Net cash from operating activities for Q1 2026 totaled $1.3 billion, a decrease of $102 million from the prior year, which it attributed in part to the cash-out of equity awards related to the Exact Sciences acquisition.
Key figures
Quarter ended March 31, 2026
- Revenue
- $11.2B
- Operating income
- $1.3B
- Net income
- $1.1B
- EPS
- $0.61
- Operating cash flow
- $1.3B
From the XBRL financial data filed with the SEC · not processed by AI.
Summary
AI-writtenAnalysis scope · Management's discussion (MD&A)We analyzed the Management's Discussion and Analysis (MD&A) section. Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.
Exact Sciences Acquisition Consideration and Funding
The company said it completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion, paying $105 per share in cash. It said the deal was funded mainly through the issuance of $20 billion of long-term debt in March 2026, with the remainder funded by cash on hand.
Source · Based on the MD&A text of the filing
Quarterly Net Sales Growth and Segment Performance
The company said total net sales rose 3.8% in Q1 2026 excluding the impact of foreign exchange, mainly reflecting higher product sales in the Medical Devices and Established Pharmaceutical Products segments. It said Nutritional Products sales declined due to lower sales volumes.
Source · Based on the MD&A text of the filing
Higher SG&A and R&D Expenses
Abbott said SG&A expenses rose $679 million to $3.7 billion, or 22.2%, in Q1 2026, citing the acquisition and integration of Exact Sciences and stock-based compensation expense from the cash-out of equity awards tied to the deal as the main factors. R&D expenses rose $51 million to $767 million.
Source · Based on the MD&A text of the filing
Cash Decline and Operating Cash Flow
The company said cash and cash equivalents fell from $8.5 billion on December 31, 2025 to $6.8 billion on March 31, 2026. Net cash from operating activities for Q1 2026 totaled $1.3 billion, a decrease of $102 million from the prior year, which it attributed in part to the cash-out of equity awards related to the Exact Sciences acquisition.
Source · Based on the MD&A text of the filing
AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.
Original filing
The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.
Loading the filing text…